Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July…
Related Posts
CoinShares’ Butterfill suggests ’continued hesitancy’ among investors
Matrixport’s head of strategy said he believes the market is currently in a “wait-and-see environment” but could shift…
Dogecoin and Shiba Inu investors focus on Dogen for its 100x growth potential
Dogen is capturing attention for its growth potential, exciting Dogecoin and Shiba Inu enthusiasts alike. #partnercontent
Berkshire Hathaway vice chair Charlie Munger passes away at age 99
The vice chairman of multinational holding company Berkshire Hathaway once described cryptocurrency and artificial intelligence as “overhyped” and…